Get the Stockscreener App
0.0933
1.53%
0.0015
Cns Pharmaceuticals Inc stock is traded at $0.0933, with a volume of 3.54M.
It is up +1.53% in the last 24 hours and down -15.96% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$0.0918
Open:
$0.092
24h Volume:
3.54M
Relative Volume:
0.25
Market Cap:
$5.28M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.00132
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-2.00%
1M Performance:
-15.96%
6M Performance:
-50.16%
1Y Performance:
-99.24%
1-Day Range:
$0.0913
$0.095
1-Week Range:
$0.0905
$0.099
52-Week Range:
$0.082
$23.90
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
0.0932 | 5.28M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.87 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.32 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.64 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Ladenburg Thalmann slashes price target on Cns Pharmaceuticals Inc [CNSP] – find out why. - The DBT News
Cns Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
CNSP’s price-to-book ratio: An indicator of the company’s performance - US Post News
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity - ACCESS Newswire
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - ACCESS Newswire
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - ACCESS Newswire
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date - ACCESS Newswire
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - ACCESS Newswire
CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN
Central Nervous System (CNS) Therapeutics Market Forecast - GlobeNewswire
Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region - 24matins.uk
CNS Pharmaceuticals (NASDAQ:CNSP) Trading Up 6.5% – Here’s Why - Defense World
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
Does Cns Pharmaceuticals Inc (NASDAQ: CNSP) Still Need To Convince Analysts? - Stocks Register
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
CNS Pharmaceuticals Announces Upcoming Virtual Analyst and Investor Day - Defense World
Cns Pharmaceuticals Inc (NASDAQ: CNSP): An Enticing Stock To Watch - Stocks Register
CNS Pharmaceuticals Hosts Virtual Analyst and Investor Day - Nasdaq
CNS Pharmaceuticals (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11 - Barchart
CNS Pharmaceuticals sets date for virtual investor event By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 - AccessWire
CNS Pharmaceuticals to Host Virtual Investor Day: Spotlight on Breakthrough Brain Cancer Treatments - StockTitan
CNS Pharmaceuticals gains shareholder nod for reverse split, warrant repricing - Investing.com
CNS Pharma's Berubicin Shows Higher Patient Retention in Pivotal GBM Trial | CNSP Stock News - StockTitan
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma - The Globe and Mail
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 4.3% – Here’s What Happened - Defense World
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart
CNS Pharmaceuticals to Present Berubicin GBM Trial Data at SNO 2024 Annual Meeting | CNSP Stock News - StockTitan
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan
CNS Pharmaceuticals Inc (CNSP) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc - GuruFocus.com
CNS Pharmaceuticals: Financial Results and Strategic Moves - TipRanks
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
CNS Pharmaceuticals’ $3 Million Common Stock Offering - Global Legal Chronicle
Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit - StockTitan
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):